RE:RE:RE:NMIBC Patients talk treatments !Given the new optional maintenance treatment, we may be about to find out:
Optional Maintenance Study II Treatment - Patients currently receive a mandatory maintenance Study II Treatment at 180 days; however, this has been optimized to allow optional maintenance Study II Treatments, at the discretion of the Principal Investigator ("PI") based on the patient's response. For patients who have achieved a CR or IR at any point in time and have demonstrated a duration of that CR or IR, no further maintenance Study II Treatments would be administered; however, if the patient recurs at any scheduled assessment visit (i.e.: 90, 180, 270, 360 or 450 days), then that patient would be eligible to receive up to 2 maintenance Study II Treatments at the discretion of the PI to assist the patient in achieving a CR. There are
8 treated patients who are not CR who haven't hit 450 days yet who may be eligible for extra treatments. There are also
15 NR patients and 2 IR (2 full doses) patients evaluated at 450 days. Some of them could possibly be eligible for more treatments.
There will also be another
41 patients (4 of them already treated) to be evaluated who might be able to take advantage of this optimization if the need arises.
stocksnbonds458 wrote: Since the Ruvidar treatment is so minimally invasive, at some point in the future would not multiple treatments given over the course of time increase that CR rate significantly higher than 30% for most any type of cancer the treatment is indicated for?